Minneapolis Heart Institute Foundation

Heart Failure Research Update

Q1 2025

View as Webpage

News & Updates

Alleviant received FDA IDE and breakthrough device designation and will begin their pivotal trial for patients with HFrEF
THT 2025 will be held this week on February 11-13 in Boston, MA

Study Spotlight:

GenePHIT/ASK-CHF 2

Description

A gene therapy phase 2 trial (AB-1002) for patients with non-ischemic NYHA Class III symptoms of Heart Failure.

Enrolling Patients with:

Chronic non-ischemic NYHA Class III Heart Failure
LVEF 15%-35%
6MWT distance >50 meters
Medically stable, NYHA Class III CHF for 4 weeks

Principal Investigator:

Dr. Jay Traverse

Contact:

Zach Fultz

Zachary.Fultz@allina.com

Phone: (612) 863-9312

Recruiting Studies

Device

Studies	Description	PI
ALLAY-HF Alleviant Medical	No-implant interarterial shunt	Dr. Peter Eckman
ALT-FLOW ll Edwards Lifesciences	Transcatheter interarterial shunt	Dr. Mike Samara
CORCINCH 5019 Ancora Heart	AccuCinch Ventricular Restoration System	Dr. Peter Eckman
AIM HIGHer Impulse Dynamics	Cardiac contractility modulation in HFpEF	Dr. Mike Samara
OPTIMIZER PAS Impulse Dynamics	Cardiac contractility modulation in HFrEF	Dr. Jay Sengupta

Gene Therapy

GenePHIT/

ASK-CHF 2

AskBio

Gene therapy trial for patients with non-ischemic NYHA Class III symptoms of Heart Failure

Dr. Jay Traverse

Transplant/VAD

OHP Registry ll

Transmedics

Clinical outcomes of heart transplant recipients that used the Organ Care Heart Perfusion System

Dr. Benjamin Sun

Pipeline Studies

CONTEMP-ICD

U of Rochester

Benefit and risks of ICD implantation in patients with HF who have a low risk of sudden death

Dr. Mosi Bennett

INNOVATE

BrioHealth Solutions

Safety and efficacy of the BrioVAD System vs. HeartMate 3 Left Ventricular Assist System

Dr. Benjamin Sun

FDA=Food and Drug Administration; ICD=Implantable Cardioverter-Defibrillator; IDE=Investigational Device Exemption; HFrEF=Heart Failure with Reduced Ejection Fraction; GDMT= Guideline-Directed Medical Therapy; PI=Principal Investigator; SVC=Superior Vena Cava; VAD=Ventricular Assist Device; OHP= Organ Care Heart Perfusion System

For more information, please contact Julianne Feola at julianne.Feola@allina.com; Ph: (585)944-8268